sch66336 Report issue

Small molecule Experimental First in Class
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1
  • InChIKey: DHMTURDWPRKSOA-RUZDIDTESA-N
  • Mol. Mass: 638.83
  • ALogP: 5.91
  • ChEMBL Molecule:
    lonafarnib  
More Chemistry

Pharmacology

Alternative names

1-piperidinecarboxamide, 4(2-(4-(11r-3,10-dibromo-8-chloro-6,11-dihydro-5h-benzo(5,6)cyclohepta(1,2-b)pyridine-11-yl)-1-piperidinyl)-2-oxoethyl)- | 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5h-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(r)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide | (+)4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5h-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide | lonafarnib | sch66336 | sch 66336 | sch-66336

Organizations (25)

Research & Development (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (34)

Approved Indications (1)


 

Progeria

Experimental Indications - Clinical Trial Phases 1-4 (34)


 

Astrocytoma (Phase 1)

Blast Crisis (Phase 1/Phase 2)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 1)

Glioblastoma (Phase 2)

Gliosarcoma (Phase 1)

Head and Neck Neoplasms (Phase 2)

Hepatitis D (Phase 2)

Hepatitis D, Chronic (Phase 2)

Leukemia (Phase 1/Phase 2)

Leukemia, Lymphoid (Phase 1/Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 3)

Liver Diseases (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 1)

Myelodysplastic Syndromes (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1/Phase 2)

Progeria (Phase 2)

Prostatic Neoplasms (Phase 1/Phase 2)

Sarcoma (Phase 1)

Stomach Neoplasms (Phase 1/Phase 2)

Supratentorial Neoplasms (Phase 1)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 36
  • # of Trial Organizations: 25

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue